metabolicMolecular Weight: 1817.1Reviewed: 2026-03-26

Fragment 176-191

HGH Frag 176-191 • AOD-9604 Fragment

A 16-amino acid fragment of human growth hormone that selectively promotes fat metabolism without the side effects of full HGH. Research suggests targeted fat loss properties.

Quick Answer

Fragment 176-191 searches cluster around dosing, side effects, and what the peptide is actually supposed to do. The page needs a fast, plain-language answer before deeper protocol detail.

Mechanism

Fragment of human growth hormone (amino acids 176-191) that promotes fat breakdown without affecting blood sugar or growth. Selectively targets fat cells.

Half-Life

30 minutes

Administration

Subcutaneous

Technical Protocol

Fragment 176-191: Comprehensive Research Guide

Overview

Fragment 176-191 (also known as HGH Frag 176-191 or AOD-9604 Fragment) is a 16-amino acid peptide derived from the C-terminal region of human growth hormone (amino acids 176-191). This fragment has been studied for its selective fat-burning properties without the systemic effects of full HGH.

Mechanism of Action

Selective Fat Metabolism

  • Lipolysis: Promotes breakdown of stored fat (triglycerides)
  • Fat Cell Targeting: Specifically targets adipocytes (fat cells)
  • No Growth Effects: Does not stimulate growth hormone receptors
  • Metabolic Enhancement: Increases metabolic rate in fat tissue

Key Differences from HGH

  • No Blood Sugar Impact: Does not affect glucose metabolism
  • No Growth Stimulation: Does not promote muscle or bone growth
  • Targeted Action: Primarily affects fat cells
  • Shorter Half-Life: Rapid clearance from system

Research Applications

Fat Loss Research

  • Targeted Fat Reduction: May reduce stubborn fat deposits
  • Metabolic Rate: Increases fat metabolism
  • Body Composition: Improves body fat percentage
  • Spot Reduction: Potential for localized fat reduction

Comparison to AOD-9604

  • Similar Structure: Related to AOD-9604
  • Different Effects: May have distinct mechanisms
  • Research Status: Both under investigation

Dosage Protocols

Standard Protocol

  • Dose: 200-500 mcg daily
  • Typical: 300 mcg twice daily
  • Timing: Morning and evening
  • Administration: Subcutaneous injection

Cycle Recommendations

  • Duration: 8-12 weeks
  • Cycles: 8 weeks on, 4 weeks off
  • Stacking: Often combined with other peptides

Side Effects

  • Minimal: Generally well-tolerated
  • Injection Site: Mild irritation possible
  • No Hormonal: Does not affect hormone levels
  • No Blood Sugar: Safe for diabetics

Storage

  • Temperature: 2-8°C (refrigerated)
  • Light: Protect from light
  • Reconstituted: Stable for 2-3 weeks refrigerated

This information is for research and educational purposes only.

Answer-First Research Snapshot

Evidence

Search volume is still modest, but user intent is very specific and commercially valuable. This is exactly the kind of page that benefits from answer-first formatting.

Dosage Context

Protocol framing should explain range, timing assumptions, and why half-life questions matter for interpreting schedule claims.

Status

Keep the page anchored in research framing and evidence limitations rather than exaggerated body-composition promises.

Pair dosing guidance with side-effect and half-life explanations.

Address user intent directly in the title and FAQ.

Link to half-life and protocol hubs from above the fold.

Peer-Reviewed Citations

AOD9604: a peptide that regulates fat metabolism

Heffernan M, et al. • Int J Obes (2001)

Access Research

Frequently Asked Questions

What do users most want to know about Fragment 176-191?

They usually want dosage context, expected mechanism, half-life assumptions, and whether side-effect claims are grounded in real evidence.

Why should half-life be visible on this page?

Because scheduling and interpretation questions appear repeatedly in search data, and half-life provides context for those protocol discussions.

How should Fragment 176-191 be stored?

Store at 2-8°C, protect from light

Continue the Research Path

Related Metabolic Peptides